Business description
Basilea Pharmaceutica AG, founded in 2000, is a commercial stage biopharmaceutical company developing products that address the medical challenge of increasing resistance and non-response to current treatment options in the therapeutic areas of bacterial infections, fungal infections and cancer. With two commercialized drugs, the company is committed to discovering, developing and commercializing innovative pharmaceutical products to meet the medical needs of patients with serious and life-threatening conditions. The company has a portfolio of marketed drugs: Zevtera®/Mabelio® (ceftobiprole) is an intravenous antibiotic from the cephalosporin class amd Cresemba® (isavuconazole) is an intravenous and oral antifungal from the azole class. Furthermore Basilea's pipeline includes three early-stage oncology drug candidates. Basilea Pharmaceutica AG is headquartered in Basel, Switzerland.
Management board & Supervisory board
| CEO |
| David Veitch |
| Management board |
| Adesh Kaul, Dr. Gerrit Hauck, Dr. Laurenz Kellenberger, Dr. Marc Engelhardt |
| Supervisory board |
| Domenico Scala, Dr. Martin Nicklasson, Dr. Nicole Onetto, Dr. Thomas Werner, Ronald Scott, Steven D. Skolsky |
Company data
| Name: |
Basilea Pharmaceutica AG |
| Address: |
Grenzacherstraße 487,CH-4005 Basel |
| Phone: |
+41-61-606-1111 |
| Fax: |
+41-61-606-1112 |
| E-mail: |
info_basilea@basilea.com
|
| Internet: |
www.basilea.com |
| Industry: |
Healthcare |
| Sector: |
Pharmaceutical Industry |
| Sub sector: |
Pharmaceuticals |
| End of financial year: |
12-31 |
| Free Float: |
90.35% |
| IPO date: |
2004-03-25 |
